Acquisition - July 3, 2015
Novo to End Tresiba in Germany
Novo Nordisk will stop distribution of its once-daily insulin drug Tresiba after price negotiations with Germany’s health insurance fund trade group broke down, according to BioSpace.com. Company officials indicated they could not come to an agreement on price with GKV-Spitzenverband, which wanted to set the price level equal to that of human insulin. The company […]
Clinical Trials - June 8, 2015
Novo Drug Works During Ramadan Fast
Adults with type 2 diabetes treated with Novo Nordisk’s Victoza®, in combination with metformin, experienced similar improvements in blood glucose control while fasting during the four weeks of Ramadan compared with sulfonylurea (SU) plus metformin, according to a recent study. People treated with Victoza® also demonstrated greater weight loss and fewer confirmed hypoglycemic episodes compared with […]
Clinical Trials - May 11, 2015
Saxenda Benefits Beyond Weight Loss
New data from a post-hoc analysis of the phase 3a SCALE™ clinical trial program were presented at the European Congress on Obesity (ECO), demonstrated that Novo Nordisk’s Saxenda (liraglutide 3 mg) has benefits beyond weight loss. “…The post-hoc analysis confirmed that weight loss has a positive impact on a number of cardiometabolic risk factors, including […]
In a new job - May 7, 2015
Lundbeck Hires Novo Exec
The man considered most likely to take over the helm at Novo Nordisk, Kåre Schultz, had a good reason for suddenly leaving the company. He accepted the top job at Lundbeck, which has been without a chief executive since its CEO left amid controversy in November 2014. Lundbeck announced Schultz’s appointment Wednesday along with first-quarter […]
In a new job - May 1, 2015
Novo Nordisk Exec Resigns
Novo Nordisk’s top executive candidate and current company president Kåre Schultz abruptly resigned after spending 26 years at the company. Jakob Riis, executive vice president for the company’s operations in China, Pacific and Marketing, is considered the most likely successor to exiting CEO Lars Rebien Soerensen. The search for a new CEO will continue. Soerensen […]
Acquisition - April 21, 2015
Novo Nordisk, Janssen Sign Pact
Novo Nordisk A/S and Janssen Biotech, Inc. have signed an agreement that will allow Janssen to acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor), according to Novo Nordisk. The […]
